Achieve Life Sciences Inc
$ 6.65
1.53%
07 Aug - close price
- Market Cap 682,683,000 USD
- Current Price $ 6.65
- High / Low $ 6.79 / 6.50
- Stock P/E N/A
- Book Value 0.20
- EPS -1.09
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.08 %
- ROE -4.96 %
- 52 Week High 7.11
- 52 Week Low 2.37
About
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and markets cytisinicline for smoking and nicotine addiction cessation in the United States and internationally. The company is headquartered in Vancouver, Canada.
Analyst Target Price
$14.09
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-12 | 2026-03-24 | 2025-11-06 | 2025-08-07 | 2025-05-13 | 2025-03-11 | 2024-11-07 | 2024-08-13 | 2024-05-09 | 2024-03-28 | 2023-11-09 |
| Reported EPS | -0.37 | -0.19 | -0.28 | -0.28 | -0.37 | -0.37 | -0.36 | -0.36 | -0.25 | -0.26 | -0.26 | -0.34 |
| Estimated EPS | -0.18 | -0.3 | -0.2771 | -0.26 | -0.37 | -0.37 | -0.36 | -0.29 | -0.24 | -0.25 | -0.31 | -0.37 |
| Surprise | -0.19 | 0.11 | -0.0029 | -0.02 | 0 | 0 | 0 | -0.07 | -0.01 | -0.01 | 0.05 | 0.03 |
| Surprise Percentage | -105.5556% | 36.6667% | -1.0466% | -7.6923% | 0% | 0% | 0% | -24.1379% | -4.1667% | -4% | 16.129% | 8.1081% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ACHV
2026-08-03 12:15:01
Achieve Life Sciences has appointed Ronald Dadino as Senior Vice President, Chemistry, Manufacturing and Controls (CMC) and Supply Chain, and Gloria Cosgrove as Senior Vice President, Quality. These appointments aim to strengthen the company's manufacturing, supply chain, and quality functions as it prepares for the resubmission of its New Drug Application (NDA) for cytisinicline and its anticipated U.S. commercial launch. The move is strategic, bringing in seasoned leaders to manage the transition of cytisinicline finished product manufacturing to the United States.
2026-08-03 05:30:00
Achieve Life Sciences has appointed Ronald Dadino as Senior Vice President of CMC and Supply Chain, and Gloria Cosgrove as Senior Vice President of Quality. These appointments strengthen the company's leadership in manufacturing, supply chain, and quality as it prepares for the resubmission of its New Drug Application for cytisinicline and its anticipated U.S. commercial launch. Both executives bring extensive experience in regulated pharmaceutical manufacturing and quality systems.
2026-08-02 16:10:59
Achieve Life Sciences announced a private placement aiming to raise up to $354 million, with an initial $180 million funding and an additional $174 million from warrants tied to FDA approval. This financing, led by several prominent healthcare investors, will support a Phase 3 clinical trial for cytisinicline for e-cigarette cessation and its commercialization. Concurrently, the company appointed Andrew D. Goldberg, MD, as its new CEO and a board member, effective after the closing of the private placement.
2026-07-31 20:15:01
Achieve Life Sciences, Inc. has announced the granting of stock options and restricted stock unit (RSU) awards to six new employees under its 2024 Equity Inducement Plan. These awards, totaling 1,190,000 shares for stock options and 125,000 shares for RSUs, are part of the company's efforts to attract and retain talent. The company specializes in developing cytisinicline for nicotine dependence, with ongoing studies for both smoking and e-cigarette cessation.
2026-07-31 12:10:20
Achieve Life Sciences announced new-hire equity inducement awards for six employees, comprising stock options for 1,190,000 shares and RSU awards for 125,000 shares. These awards, granted under the 2024 Equity Inducement Plan, are intended to attract and retain talent in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options and RSUs have vesting schedules over four years, supporting the company's focus on cytisinicline development for nicotine dependence.
2026-07-31 12:10:19
Achieve Life Sciences has announced the granting of new hire inducement awards, including stock options for 1,190,000 shares and RSU awards for 125,000 shares, to six new employees. These awards are part of the company's 2024 Equity Inducement Plan and are intended to attract new talent. Cytisinicline, the company's lead product, is a plant-based alkaloid being developed to treat nicotine dependence, with ongoing studies for smoking and e-cigarette cessation.
